drugset
drugset / Trial / NCT02417103

Pretreatment of Patients Expecting Bariatric Surgery With the GLP-1 Analogon Liraglutid

NCT02417103 ↗

Phase 3 Terminated 2 enrolled University Medical Center Hamburg-Eppendorf
RandomizedParallel-groupDouble-blindTreatment

Summary

The aim of this study is to investigate the effect of the treatment with the GLP-1 Analogon Liraglutide on the lipid metabolism an inflammation in adipose tissue.

Timeline

Start
2011-12
Primary completion
2016-09
Completion
2016-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Liraglutide Peptide 1.8 mg Subcutaneous

Indications

obesity disorder